Antipsychotic medications can help a person with bipolar disorder stabilize their moods, reduce agitation, and improve ...

The synergistic relationship between psychiatric medications and psychotherapy is often overlooked. By managing discreet ...

NDA submitted to U.S. FDA for CAPLYTA® as adjunctive treatment for major depressive disorder; if approved, CAPLYTA® has ...

Johnson & Johnson acquires Intra-Cellular Therapies for $14.6 billion. The biggest driver was the rights Caplyta which has ...

Shares of Intra-Cellular Therapies are surging 35% in premarket trading Monday after Johnson & Johnson said it will acquire ...

S&P Global Ratings placed Johnson & Johnson on CreditWatch with negative implications, citing its nearly $15 billion deal to acquire mental-illness drug developer Intra-Cellular Therapies.

Researchers Use Fitness Tracker Data and Machine Learning to Detect Bipolar Disorder Mood Swings ... been shown to be effective at rapidly treating depression in patients for whom standard ...

Johnson & Johnson agreed to acquire Intra-Cellular Therapies Inc., a company focused on treatments for central nervous system ...

Monitoring the longitudinal course of bipolar illness in this era of psychopharmacology is crucial both for the patient and treating physician ... patient's manic and depressive episodes at ...

Johnson & Johnson is starting the year off strong with a $14.6 billion acquisition of the biopharma firm Intra-Cellular Therapies — best known for its blockbuster drug Caplyta. The deal was announced ...